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Abstract
Objective—Using data from 2003-2012, we updated a previous analysis of trends in 
hospitalizations of HIV-infected children and adolescents in the US.
Methods—We used data from the Kids´ Inpatient Database of the Healthcare Cost and 
Utilization Project to derive nationally representative estimates of the number of hospitalizations 
and the rates per 1000 hospitalizations of select discharge diagnoses and procedures in 2003, 2006, 
2009, and 2012 among HIV-infected and HIV-uninfected children and adolescents ≤18 years, 
excluding hospitalizations for conditions related to pregnancy/delivery and neonatal diagnoses. We 
also examined trends in the prevalence of select discharge diagnoses and procedures using 
multivariable logistic regression models.
Results—During 2003-2012 the number of hospitalizations for HIV-infected children declined 
58% vs 17% for uninfected, but the odds of having discharge codes for most of the diagnoses and 
procedures studied, including death during hospitalization, remained higher among HIV-infected 
compared to uninfected children. Among HIV-infected children, the prevalence of discharge 
diagnoses for pneumonia, pneumococcal disease, and varicella/herpes zoster infections, and odds 
of death during hospitalization decreased over time, while bacterial infections/sepsis and MRSA 
increased. Among HIV-uninfected children there was no increase in diagnoses of bacterial 
infection/sepsis, but otherwise trends were similar.
Conclusion—The number of hospitalizations for HIV-infected children declined from 2003 to 
2012. The decreased prevalence of several discharge diagnoses and lower risk of death during 
hospitalization likely reflect improvements in HIV therapies and increased uptake of other 
preventive strategies. However, the increasing prevalence of discharge diagnoses for bacterial 
infections/sepsis warrants further attention and monitoring.
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Previous analysis of hospitalization trends among HIV-infected children and adolescents in 
the United States (US) from 1994-2003 indicated that there were dramatic decreases in the 
number of hospitalizations with the widespread use of highly active antiretroviral therapy 
(HAART) in the US.1 Since 2003, the pediatric HIV treatment guidelines have evolved, with 
greater emphasis on starting combination antiretroviral therapy very early in life.2,3 
Guidelines for the prevention and treatment of opportunistic infections among HIV-infected 
children have also changed during this time period.4,5 Other potential factors that may have 
more recently influenced the number of hospitalizations include increased use of preventive 
strategies, such as the pneumococcal conjugate (PCV)6 and the influenza vaccines.7
The purpose of this study was to update and expand on the previous analysis using more 
recent data to describe trends in hospitalizations for children and adolescents aged ≤18 years 
with HIV infection in the US during 2003–2012. Information on recent trends in 
hospitalizations of HIV-infected children is important in a climate of rapidly changing health 
care and practices to identify potential areas for future research.
Methods
Description of the database
The Kids´ Inpatient Database (KID) is part of the Healthcare Cost and Utilization Project 
(HCUP) of the Agency for Healthcare Research and Quality (AHRQ) and is the largest 
publicly-available all-payer pediatric inpatient care database in the US.8 It is released every 
three years; we used 2003, 2006, 2009, and 2012 data for this analysis. The KID is a sample 
of pediatric discharges (defined as discharges where a patient was ≤20 years at admission) 
from all community, non-rehabilitation hospitals in participating states.8,9
Pediatric discharges are stratified by reason for hospital stay (uncomplicated in-hospital 
birth, complicated in-hospital birth, and all other pediatric cases). The KID is constructed 
using systematic random sampling to select a percentage of discharges by reason for hospital 
stay.8 The KID contains information on about 3 million hospital stays from an average of 
about 3800 hospitals for each year studied. The discharge records in the KID do not contain 
a patient identifier, and thus repeat hospitalizations cannot be identified. To obtain national 
estimates, hospitals are post-stratified by six characteristics (geographic region, ownership, 
rural/urban location, teaching status, bed size, and hospital type), and discharge weights for 
each record are created to account for the complex sampling design.8
Hospital discharge diagnoses and procedures were coded according to the International 
Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) and the Clinical 
Classifications Software (CCS) tool, developed by the AHRQ for clustering diagnoses and 
procedures into clinically meaningful categories.10
Study Design and Statistical Analysis
This analysis examined trends from 2003 to 2012 in the burden of hospitalizations among 
HIV-infected children and adolescents. For comparison, these same trends were examined in 
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hospitalizations of HIV-uninfected children. The term “children” is used throughout the 
paper and refers to both children and adolescents. Data from children who were ≤18 years 
were included in these analyses for consistency with the age range used in the prior analysis.
1 Hospitalizations for conditions related to pregnancy and delivery (ICD-9-CM codes are in 
Supplemental Digital Content 1, appendix) and hospitalizations for neonatal diagnoses 
(using the neomat variable in the KID that flags hospitalizations for neonates) were 
excluded.
Our outcomes of interest included deaths during hospitalization, hospital charges, and select 
discharge diagnoses and procedures. Hospital charges were adjusted to 2012 dollars using 
the Bureau of Labor Statistics’ Consumer Price Index. Discharge diagnoses of interest 
included Pneumocystis jiroveci pneumonia (PCP), pneumonia, pneumococcal disease, 
bacterial infections/sepsis, mycoses, Mycobacterium avium complex infections, varicella/
herpes zoster infections, lymphocytic interstitial pneumonia (LIP), influenza, and 
methicillin-resistant Staphylococcus aureus (MRSA). Procedures of interest included 
injection of antibiotic, diagnostic spinal tap, esophagogastroduodenoscopy, percutaneous 
gastrostomy, transfusion of packed red blood cells, and bronchoscopy. The ICD-9-CM and 
CCS codes used are in Supplemental Digital Content 1 (appendix).
Our primary independent variables were HIV status (defined by CCS code 5) and year of 
hospitalization. For 2003 and 2012, hospitalized patients were described by 
sociodemographic and hospital characteristics, including gender, age group (0-4 years, 5-9 
years, 10-14 years, and 15-18 years), expected primary payer (public [Medicare/Medicaid], 
private, and other [self-pay, no charge, and other]), hospital location (rural, urban non-
teaching, or urban teaching), and hospital region (Northeast, Midwest, South, or West). Race 
was not examined because it is often not reported by states or there are inconsistencies and 
missing values.11
Wald χ2 tests with a significance level of 0.05 were used to assess differences in the 
characteristics of hospitalized children with and without HIV infection. Student’s t tests 
were used to compare the average length of hospital stay, inflation adjusted hospital charges, 
and number of discharge diagnoses and procedures per hospitalization by HIV infection 
status.
For 2003, 2006, 2009, and 2012, we compared the rates of death and select discharge 
diagnoses and procedures per 1000 hospitalizations among HIV-infected and HIV-
uninfected children. Multivariable logistic regression models were used to assess the odds of 
death during hospitalization and of having discharge codes for each diagnosis and procedure 
for HIV-infected versus HIV-uninfected children, adjusting for patient gender and age group 
(0-9 years and 10-18 years). To assess trends over time, we compared data across the four 
study years: 2003 (reference period), 2006, 2009, and 2012, in multivariable logistic 
regression models, stratified by HIV status and adjusting for patient gender and age group 
(0-9 years and 10-18 years). Additionally, we evaluated differences in trends by HIV status 
testing the significance of an interaction term for study year by HIV status. To assess trends 
in inflation adjusted mean hospital charges by HIV status, multivariable linear regression 
was performed adjusting for patient gender and age group (0-9 years and 10-18 years).
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All statistical analyses were conducted with SAS callable SUDAAN, version 9.3 (Research 
Triangle Institute, NC).
Results
We estimated there were 1343 hospitalizations among children with an HIV diagnosis in the 
US in 2012 compared with 3172 in 2003, which is a 58% decrease (Table 1); in comparison, 
hospitalizations among HIV-uninfected children decreased by 17% during this time period. 
In both 2003 and 2012, HIV-infected as compared to uninfected children had longer mean 
hospital stays (2003: 7.0 vs 3.8 days [P <0.001]; 2012: 8.0 vs 4.0 days [P <0.001]), higher 
mean hospital charges (2003: $33 867 vs $18 578 [P<0.001]; 2012: $69 595 vs $33 061 [P 
<0.001]), and higher mean number of discharge diagnoses (2003: 5.4 vs 3.0 [P <0.001]; 
2012: 8.6 vs 4.5 [P <0.001]) and procedures (2003: 1.3 vs 0.9 [P<0.001]; 2012: 1.7 vs 1.0 
[P<0.001) per hospitalization. From 2003 to 2012, the mean hospital charges for HIV-
infected children increased by 105% while mean hospital charges for HIV-uninfected 
children increased by 78%.
Girls comprised a higher proportion of hospitalizations than boys among HIV-infected 
children in 2003 but not in 2012, while boys comprised a higher proportion among HIV-
uninfected hospitalizations in both 2003 and 2012 (Table 1). For both 2003 and 2012, the 
0-4 age group accounted for the highest percentage of hospitalizations among HIV-
uninfected children, and the 15-18 year age group accounted for the highest percentage of 
hospitalizations among HIV-infected children, with adolescents 15-18 years accounting for 
33.1% of hospitalizations among HIV-infected children in 2003 and 52.9% in 2012 (Table 
1). However, the estimated number of HIV-infected children’s hospitalizations decreased for 
all age groups from 2003 to 2012.
Overall, there was a 62% decrease in the number of hospitalizations among HIV-infected 
girls from 2003 to 2012 and a decrease of 52% for boys (Table 1).
In both 2003 and 2012, most HIV-infected pediatric patients had Medicaid or Medicare as 
their expected payer and were hospitalized mainly in urban teaching hospitals (Table 1). The 
South had the highest burden of all HIV pediatric hospitalizations in both 2003 and 2012. 
These characteristics were similar for HIV-uninfected children’s hospitalizations, except that 
most HIV-uninfected children had private insurance as their primary expected payer in 2003.
The rate of death per 1000 hospitalizations decreased by 48% from 2003 to 2012 for HIV-
infected children, but remained higher than that of HIV-uninfected hospitalized children in 
2012 (9.3/1000 hospitalizations compared with 3.4/1000 hospitalizations) (Table 2). HIV-
infected as compared with uninfected children had greater odds of death during 
hospitalization in both 2003 and 2012 (2003: adjusted odds ratio [aOR], 3.76; 95% 
confidence interval [CI]: 2.61-5.42 and 2012: aOR, 2.76; 95% CI: 1.38-5.52). Additionally, 
the odds of having discharge codes for most diagnoses and procedures of interest were 
higher among hospitalizations of HIV-infected compared to HIV-uninfected children in both 
2003 and 2012 (Table 2). Adjusting for age and sex generally had little effect on the 
estimated associations presented in Table 2, with a small number of exceptions. For 
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example, the unadjusted OR for HIV and bacterial infections/sepsis was 1.02 (95% CI: 0.91, 
1.15), while the adjusted OR was 1.41 (1.22-1.62). This association was driven by an OR of 
2.10 (1.81, 2.44) for bacterial infections/sepsis among HIV-infected compared to uninfected 
children aged 10-18 years. This association was not significant for children aged <10 years 
(OR: 0.84 [0.68, 1.03]). The only conditions for which there was not a significant difference 
between the two groups included influenza and MRSA for 2003. The rates of 
hospitalizations with discharge diagnoses for bacterial infection/sepsis and pneumonia (per 
1000 hospitalizations) for HIV-infected and uninfected children in 2003, 2006, 2009, and 
2012 are presented in Figure 1 and for varicella/herpes zoster and MRSA in Figure 2.
Among hospitalized HIV-infected children, the odds of discharge diagnoses for pneumonia, 
pneumococcal disease, and varicella/herpes zoster infections decreased significantly from 
2003 to 2012 (pneumonia: aOR, 0.66; 95% CI: 0.51-0.87, pneumococcal disease: aOR, 0.30; 
95% CI: 0.10-0.87, varicella/herpes zoster infections: aOR, 0.44; 95% CI: 0.23-0.85; Table 
3; Figs 1&2). Conversely, among hospitalized HIV-infected children, the odds of discharge 
diagnoses for bacterial infections/sepsis and MRSA increased from 2003 to 2012 (bacterial 
infections/sepsis: aOR, 1.26; 95% CI: 1.03-1.55, MRSA: aOR, 6.75; 95% CI: 2.34-19.45; 
Table 3). The odds of a discharge diagnosis for influenza were significantly greater in 2009 
compared to 2003 among HIV-infected children (aOR, 4.06; CI: 2.32-7.11; Table 3).
Similar trends were observed among hospitalizations of HIV-uninfected children for deaths 
during hospitalization and discharge diagnoses for pneumonia, pneumococcal disease, 
varicella/herpes zoster infections and MRSA (Table 3; Figs 1&2). Conversely, the decreases 
observed for hospitalizations with the discharge diagnosis of pneumonia were greater for 
HIV-infected, compared with uninfected children (test for interaction: P=.02). There were 
also significant interactions between year and infection status for discharge diagnoses for 
bacterial infections/sepsis and influenza. Among HIV-uninfected children, the odds of 
discharge diagnoses for bacterial infections/sepsis remained fairly stable (P=.02), and 
influenza generally decreased over time with an increase in 2009 that was more modest than 
for HIV-infected children (P=.01). In addition, there were increases in discharge diagnoses 
for mycoses, Mycobacterium avium infections, and cytomegalovirus among HIV-uninfected 
children (Table 3).
Regarding procedures of interest, use of antibiotic injections decreased significantly for both 
HIV-infected and uninfected hospitalized children (Table 3). The odds of other procedures 
studied did not change significantly for HIV infected children.
Discussion
In this analysis of multiple years of nationally representative data on hospital admissions in 
the US, we found the estimated numbers of hospitalizations among HIV-infected children 
and adolescents ≤18 years decreased by 58% from 2003 to 2012. US-wide HIV surveillance 
data a decrease in the number of youth ≤19 years living with a diagnosed HIV infection in 
the US (from an estimated 11,997 in 2009 to 9,790 in 2012).12,13 The decrease in the 
estimated numbers of hospitalizations among HIV-infected children and adolescents ≤18 
years mirrors the 71% decrease from 1994 to 2003 noted in our previous analysis.1 That 
Hurst et al. Page 5













decrease was noted to have occurred since the advent of highly active antiretroviral therapy 
in the US around 1997. Since 2003, antiretroviral therapy regimens have improved and 
treatment has become more aggressive, which may contribute to this continued decline.
3,14,15
Another factor that may be contributing to the decreasing numbers of hospitalizations could 
be the shift in age patterns as HIV-infected adolescents age out of this population. From 
2009 to 2014, the overall estimated rates of new HIV diagnoses for adolescents 15-19 years 
has been decreasing (from 10.3 to 8.7 per 100,000 population).12,13 The rates for 
adolescents 13-14 years and children younger than 13 have been more stable from 
2009-2014 and are fairly low (0.4 and 0.3 respectively per 100,000 population in 2014).12,13
We found that the rates and odds of death during hospitalization for HIV-infected children 
decreased from 2003-2012 but were still higher than the odds for HIV-uninfected children. 
Two prior studies have shown that mortality rates for HIV-infected children are about 30 
times higher than rates for the general US pediatric population.16,17 Another study found 
declining hospitalization rates from 2003-2010 among 5–16 and 17–24 year-olds perinatally 
infected with HIV.18 While use of HAART has led to decreases in mortality for HIV-infected 
children,19 finding the optimal treatment strategies remains a challenge, particularly for 
adolescents who are likely to face adherence issues.20,21
The rates and adjusted odds ratios of most of the outcomes described in this analysis were 
higher among hospitalizations of HIV-infected children compared to HIV-uninfected 
children in all years studied (2003, 2006, 2009, and 2012). The trends examined show 
decreases in the likelihood of discharge codes for pneumonia, pneumococcal disease, and 
varicella/herpes zoster infections among hospitalized HIV-infected children, but increases in 
discharge codes for bacterial infections/sepsis and MRSA.
The increase in discharge codes for bacterial infections/sepsis is in contrast to the decrease 
noted in our previously published analysis comparing the pre-HAART (1994-1996) and 
HAART (2001-2003) eras.1 In a recent systematic review and meta-analysis of the causes of 
hospital admissions among people living with HIV worldwide, AIDS-related illnesses and 
bacterial infections were the leading causes of hospitalization among children.22 It should be 
noted that the incidence of hospitalizations with coding for sepsis has increased in the US, 
while hospitalizations with objective clinical markers of infection have remained stable or 
decreased,23 likely reflecting changes in coding practices. Although this could explain the 
increases we found in discharge diagnoses for infections in HIV-infected pediatric 
population, particularly those aged >10 years, a corresponding increase was not observed 
among HIV-uninfected children.
We found that the prevalence of hospitalizations with discharge diagnoses for pneumococcal 
disease decreased from 2003 to 2012, coinciding with the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in the US in 2000 and PCV13 in 2010.24 An 
analysis of hospitalization trends for invasive pneumococcal disease among HIV-infected 
adolescents and adults noted a significant decrease in 2004-2005 compared to 1994-1995.25 
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The Centers for Disease Control (CDC) estimates that 92.3% of children age 19-35 months 
received ≥ 3 doses of PCV in 2012.6
Invasive MRSA infection incidence in children has been reported to have increased during 
the early part of our study period,26 but there is evidence that it may be now decreasing,27,28 
consistent with our findings that the rate per 1000 hospitalizations decreased from 2009 to 
2012 for both HIV-infected and uninfected children.
The increase in incidence of discharge diagnoses of influenza in 2009 are due to the H1N1 
pandemic.29 The decreases noted for HIV-uninfected children for 2006 and 2012 compared 
to 2003 may be due to increased uptake of the seasonal influenza vaccine.7 Similar 
decreases were not noted for hospitalizations among HIV-infected children, possibly due to 
influenza vaccinations not being as effective in HIV-infected young children.30 There was a 
downward trend in hospitalizations among children with discharge diagnoses of varicella/
herpes zoster infections, in contrast to cytomegalovirus, another opportunistic viral pathogen 
for which there is no vaccine available, which has not changed. The CDC estimates that 
90.2 % of children age 19-35 months had received ≥ 1 dose of varicella vaccine in 2012,6 
and it is recommended for all but the most severely immunocompromised HIV-infected 
children.31
This study has some limitations. The sampling frame for the KID changes over time as states 
are added (e.g. 36 in 2003 and 44 in 2012), so estimates from earlier years may be subject to 
more sampling bias than later years.8 A few states prohibit the release of discharge records 
for patients with an HIV diagnosis. The KID includes discharge records for patients up to 
age 20 years at admission, but some states suppress the reporting of age for children with an 
HIV diagnosis. Although our analysis was limited to children ≤18 years, we included 
records where age was suppressed. Assuming the age distribution for these children was 
similar to those with a reported age, ~33 records in 2003 and ~67 in 2012 included may be 
for HIV-infected children >18 years old at admission. We analyzed data for all discharge 
diagnoses, so some conditions may not have been the reason for hospital admission. 
However, this provided a full picture of the morbidity burden of hospitalized HIV-infected 
children.
Other limitations include those common to research using administrative data: The data 
reflect hospital discharges rather than individual patients, so some children may be 
represented more than once for any given year, as well as across years. The resulting 
interdependence of observations could increase the likelihood that the associations measured 
were found significant, and is important to take into account when interpreting the results. 
Because of incomplete data on race, we were unable to evaluate its effect on our estimates. 
Codes used for some conditions may have poor sensitivity or positive predictive value.32,33 
Changes in health care and in coding practices over time may have influenced some of the 
trends observed. Strengths of this analysis include the large, nationally representative sample 
and the availability of charge and length of stay data.
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Our results demonstrate that despite decreasing numbers of hospitalizations among HIV-
infected children, the rates and adjusted odds of most of the outcomes examined are still 
higher among hospitalized HIV-infected children compared to HIV-uninfected children from 
2003-2012. The trends in discharge diagnoses among hospitalized HIV-infected children are 
generally similar to the trends for HIV-uninfected children with decreases in the prevalence 
of discharge codes for pneumonia, pneumococcal disease, and varicella/herpes zoster 
infections and an increase in MRSA. The most notable exception is the trend of increasing 
prevalence of discharge diagnoses for bacterial infection/sepsis among hospitalized HIV-
infected children which is not seen among HIV-uninfected children. Further research is 
warranted to address evolving trends and causes of this important issue for this population as 
it may impact treatment guidelines.
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Rates of discharge diagnoses for Bacterial Infection/Sepsis and Pneumonia per 1000 
hospitalizations among HIV-infected and uninfected children in the US in 2003, 2006, 2009, 
and 2012 (KID)
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Rates of discharge diagnoses for Varicella/Herpes Zoster and MRSA per 1000 
hospitalizations among HIV-infected and uninfected children in the US in 2003, 2006, 2009, 
and 2012 (KID)
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Table 3
Multivariable logistic and linear regression analysis for deaths, mean hospital charges, and select discharge 
diagnoses and procedures among HIV-infected and HIV-uninfected children and adolescents hospitalized in 
the US in 2003, 2006, 2009, and 2012 (Kids´ Inpatient Database)
aOR (95% CI)a
2003 (REF) 2006 2009 2012
HIV-infected
Deaths 1.0 0.95 (0.51-1.76) 0.67 (0.33-1.35) 0.60 (0.27-1.30)c









PCP 1.0 1.09 (0.68-1.75) 0.88 (0.51-1.50) 0.91 (0.54-1.55)
Pneumonia* 1.0 0.99 (0.81-1.21) 0.89 (0.70-1.14) 0.66 (0.51-0.87)
Pneumococcal disease 1.0 0.77 (0.43-1.40) 0.63 (0.30-1.31) 0.30 (0.10-0.87)c
Bacterial Infections/sepsis* 1.0 1.09 (0.90-1.31) 1.25 (1.02-1.54) 1.26 (1.03-1.55)
Mycoses 1.0 0.88 (0.67-1.16) 1.02 (0.78-1.33) 0.86 (0.65-1.13)
Mycobacterium avium complex infections 1.0c 1.02 (0.48-2.14) 1.26 (0.58-2.74) 0.73 (0.29-1.86)c
Varicella or herpes Zoster infections 1.0 1.18 (0.79-1.76) 0.96 (0.60-1.53) 0.44 (0.23-0.85)
Cytomegalovirus 1.0 1.27 (0.68-2.35) 0.90 (0.44-1.85) 1.62 (0.81-3.23)
Lymphocytic interstitial pneumonia 1.0 1.41 (0.69-2.90)c 0.61 (0.25-1.52)c 1.14 (0.47-2.78)c
Influenza* 1.0 1.23 (0.63-2.39) 4.06 (2.32-7.11) 1.25 (0.56-2.78)c
MRSA 1.0c 4.28 (1.51-12.07) 6.60 (2.35-18.50) 6.75 (2.34-19.45)
Procedures
Injection of antibiotic 1.0 0.66 (0.35-1.25) 0.47 (0.25-0.87) 0.35 (0.17-0.75)c
Diagnostic spinal tap* 1.0 0.99 (0.69-1.42) 0.85 (0.57-1.26) 1.20 (0.83-1.75)
Esophagogastroduodenoscopy 1.0 1.08 (0.65-1.80) 1.28 (0.72-2.29) 1.06 (0.58-1.92)
Percutaneous gastrostomy 1.0 1.22 (0.72-2.07) 1.09 (0.57-2.09) 0.90 (0.48-1.71)
Transfusion of packed red blood cells 1.0 1.16 (0.78-1.72) 1.43 (0.99-2.05) 1.28 (0.81-2.03)
Bronchoscopy 1.0 1.28 (0.86-1.89) 0.90 (0.57-1.42) 1.33 (0.86-2.05)
HIV-uninfected
Deaths 1.0 0.96 (0.87-1.06) 0.91 (0.83-1.01) 0.86 (0.77-0.95)









PCP 1.0 1.17 (0.85-1.60) 1.14 (0.85-1.53) 1.21 (0.91-1.61)
Pneumonia* 1.0 0.95 (0.90-1.00) 1.08 (1.03-1.15) 0.89 (0.84-0.93)
Pneumococcal disease 1.0 1.06 (0.97-1.15) 1.33 (1.22-1.45) 0.70 (0.64-0.77)
Bacterial Infections/sepsis* 1.0 1.10 (1.06-1.14) 1.03 (1.00-1.07) 1.01 (0.98-1.05)
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aOR (95% CI)a
2003 (REF) 2006 2009 2012
Mycoses 1.0 1.05 (0.99-1.12) 1.08 (1.02-1.15) 1.15 (1.08-1.23)
Mycobacterium avium complex infections 1.0 1.10 (0.83-1.46) 1.47 (1.13-1.92) 1.91 (1.49-2.45)
Varicella or herpes Zoster infections 1.0 0.95 (0.86-1.04) 0.63 (0.57-0.70) 0.54 (0.49-0.59)
Cytomegalovirus 1.0 1.17 (1.01-1.36) 1.31 (1.13-1.52) 1.47 (1.23-1.76)
Lymphocytic interstitial pneumonia 1.0 0.81 (0.64-1.02) 0.96 (0.76-1.21) 0.78 (0.57-1.06)
Influenza* 1.0 0.47 (0.43-0.51) 1.87 (1.75-2.00) 0.59 (0.54-0.63)
MRSA 1.0 2.89 (2.59-3.23) 3.30 (2.97-3.67) 2.74 (2.47-3.04)
Procedures
Injection of antibiotic 1.0 0.89 (0.62-1.27) 0.64 (0.44-0.95) 0.66 (0.44-0.99)
Diagnostic spinal tap* 1.0 0.82 (0.78-0.87) 0.75 (0.71-0.80) 0.67 (0.63-0.71)
Esophagogastroduodenoscopy 1.0 1.13 (0.99-1.29) 1.32 (1.16-1.50) 1.50 (1.33-1.70)
Percutaneous gastrostomy 1.0 1.09 (0.97-1.23) 1.09 (0.97-1.23) 1.22 (1.09-1.37)
Transfusion of packed red blood cells 1.0 1.22 (1.02-1.47) 1.41 (1.18-1.67) 1.44 (1.22-1.70)
Bronchoscopy 1.0 1.07 (0.89-1.28) 1.07 (0.90-1.27) 1.18 (1.00-1.38)
aOR, adjusted odds ratio; CI, confidence interval; REF, referent group; PCP, Pneumocystis jiroveci pneumonia
a
Adjusted for gender and age group (0-9 years and 10-18 years)
b
Multivariable linear regression adjusted for gender and age group (0-9 years and 10-18 years)
c
Derived from estimates with relative SE >30%, findings should be interpreted with caution
*
Interaction noted
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